Clinical trial · no report yet · Phase 3

EA2222

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

NCT05863195 ↗
Recruiting
ECOG-ACRIN Cancer Research Group
Deep

We haven't built an HCP commentary report on EA2222 (bevacizumab, cetuximab and 7 more in Metastatic Colorectal Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on EA2222 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
X threads	45
Podcasts	4
YouTube	1

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial
Phase: Phase 3
Status: Recruiting
Conditions: Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Liver; Stage IV Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma
Interventions: Bevacizumab; Capecitabine; Cetuximab; Computed Tomography; Floxuridine; Fluorouracil; Implantation; Intrahepatic Infusion Procedure; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Oxaliplatin; Panitumumab; Single Photon Emission Computed Tomography
Arms: Arm A (HAI, floxuridine, standard chemotherapy) · Experimental
Arm B (standard chemotherapy) · Active comparator
Enrollment: 408 (estimated)
Primary outcomes: Overall survival (OS)
Sponsor: ECOG-ACRIN Cancer Research Group
Start: Apr 10, 2024
Primary completion: Jun 30, 2029 (estimated)
Results posted: No
Registry record: NCT05863195 · updated Sep 24, 2026